Corvus soquelitinib Phase 1 atopic dermatitis data show statistically significant EASI improvement vs placebo

Corvus Pharmaceuticals, Inc.

Soquelitinib met primary endpoint with statistically significant EASI improvement vs placebo at day 28 (p=0.036).
Cohort 3 (200 mg BID) achieved 64.8% mean EASI reduction vs 34.4% for placebo.
In cohort 3, 50% of evaluable patients (4/8) had a ≥4-point itch reduction (PP-NRS) at day 28.
No safety signals; soquelitinib well tolerated with no DLTs and only one grade 1 AE (nausea).
Extension cohort (200 mg BID, 8-week treatment) enrollment has been initiated.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.